DS
RCUS icon

David Shaw’s Arcus Biosciences RCUS Stock Holding History

David Shaw’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Sell
96,417
-162,983
-63% -$4.03M ﹤0.01% 2855
2026
Q1 		$5.6M Buy
259,400
+173,830
+203% +$3.75M ﹤0.01% 2090
2025
Q4 		$2.04M Buy
85,570
+65,699
+331% +$1.34M ﹤0.01% 3033
2025
Q3 		$270K Sell
19,871
-31,453
-61% -$327K ﹤0.01% 4160
2025
Q2 		$418K Sell
51,324
-4,717
-8% -$40.3K ﹤0.01% 3715
2025
Q1 		$440K Buy
+56,041
New +$650K ﹤0.01% 3569
2024
Q4 		– Sell
-13,501
Closed -$206K – 4785
2024
Q3 		$206K Sell
13,501
-17,264
-56% -$272K ﹤0.01% 4142
2024
Q2 		$469K Sell
30,765
-36,777
-54% -$594K ﹤0.01% 3659
2024
Q1 		$1.28M Buy
+67,542
New +$1.17M ﹤0.01% 2927
2023
Q3 		– Sell
-9,995
Closed -$203K – 4445
2023
Q2 		$203K Buy
+9,995
New +$190K ﹤0.01% 3734
2023
Q1 		– Sell
-26,804
Closed -$554K – 4784
2022
Q4 		$554K Buy
+26,804
New +$738K ﹤0.01% 3800
2022
Q2 		– Sell
-44,087
Closed -$1.39M – 5693
2022
Q1 		$1.39M Sell
44,087
-288,907
-87% -$9.68M ﹤0.01% 3633
2021
Q4 		$13.5M Buy
332,994
+140,031
+73% +$5.43M 0.01% 1397
2021
Q3 		$6.73M Sell
192,963
-161,983
-46% -$5.04M 0.01% 1842
2021
Q2 		$9.75M Sell
354,946
-204,363
-37% -$5.84M 0.01% 1520
2021
Q1 		$15.7M Sell
559,309
-10,024
-2% -$349K 0.02% 1075
2020
Q4 		$14.8M Sell
569,333
-44,704
-7% -$1.08M 0.01% 1122
2020
Q3 		$10.5M Buy
614,037
+168,755
+38% +$3.77M 0.01% 1213
2020
Q2 		$11M Buy
+445,282
New +$12M 0.01% 1137
2020
Q1 		– Sell
-33,100
Closed -$334K – 4188
2019
Q4 		$334K Buy
+33,100
New +$278K ﹤0.01% 3589

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

David Shaw's RCUS Position: Q2 2026 in Review

David Shaw reduced its Arcus Biosciences (RCUS) stake by 63% in Q2 2026, selling an estimated $4.03M and leaving 96,417 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2855.

David Shaw first reported a position in RCUS in Q4 2019 and has held it in 20 quarters since. The position peaked at $15.7M in Q1 2021. 228 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • David Shaw held 96,417 shares of Arcus Biosciences worth $2.97M as of Q2 2026.
  • David Shaw sold 162,983 Arcus Biosciences shares in Q2 2026, an estimated $4.03M.
  • Arcus Biosciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2855 holding.
  • David Shaw first reported a position in Arcus Biosciences in Q4 2019 and has held it in 20 quarters since.
  • David Shaw's Arcus Biosciences position peaked at $15.7M in Q1 2021.
  • 228 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.